Drug-coated balloons in the lower limb

Journal of Cardiovascular Surgery

Volumn 52, Issue 2, 2011, Pages 235-243

  Zeller, T ^a   Schmitmeier, S ^b   Tepe, G ^c   Rastan, A ^a  

^a UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

^b INNORA GMBH   (Germany)

^c Rosenheim Hospital   (Germany)

Author keywords

Angioplasty; Drug eluting balloon; Paclitaxel; Peripheral artery disease

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; CLOPIDOGREL; COTAVANCE PACCOACATH; DESTINY; FREEPAC; IOPROMIDE; NITINOL; PACCOCATH; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR; UNCLASSIFIED DRUG; UREA; YUKON BTK; ZILVER PTX;

ARTERY INTIMA PROLIFERATION; ARTERY LESION; ATHERECTOMY; BALLOON; BALLOON CATHETER; BARE METAL STENT; BLOOD VESSEL CALCIFICATION; CATHETER; DRUG COATED BALLOON; DRUG EFFICACY; DRUG ELUTING STENT; EXTRACELLULAR MATRIX; FEMORAL ARTERY; FEMOROPOPLITEAL ARTERY LESION; HUMAN; IN-STENT RESTENOSIS; LIMB ISCHEMIA; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; REVASCULARIZATION; REVIEW; SUSTAINED DRUG RELEASE; VASCULAR PATENCY;

ANGIOPLASTY, BALLOON; ANIMALS; CARDIOVASCULAR AGENTS; COATED MATERIALS, BIOCOMPATIBLE; EQUIPMENT DESIGN; EVIDENCE-BASED MEDICINE; HUMANS; LOWER EXTREMITY; PERIPHERAL ARTERIAL DISEASE; TIME FACTORS; TREATMENT OUTCOME; VASCULAR PATENCY;

EID: 79957668667     PISSN: 00219509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA Fowkes FG et al. Inter-society consensus for the management of peripheral arterial disease. Int Angiol 2007;26:81-157.
2. Beschorner U, Sixt S, Schwarzwälder U, Rastan A, Mayer C, Noory E et al. Recanalization of chronic occlusions of the superficial femoral artery using the Outback™ re-entry catheter: a single centre experience. Cath Cardiovasc Intervent 2009,74:934-8.
3. Johnston KW Femoral and popliteal arteries: reanalysis of results of balloon angioplasty. Radiology 1992;183:767-71.
4. Schillinger M, Sabeti S, Loewe C, Dick P, Amighi J, Mlekusch W et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med 2006;354:1879-88. (Pubitemid 43872689)
5. Söder HK, Manninen HI, Jaakkola P, Matsi PJ, Räsänen HT, Kaukanen E et al. Prospective trial of infrapopliteal artery balloon angioplasty for critical limb ischemia: angiographic and clinical results. J Vasc Interv Radiol 2000;11:1021-31.
6. Dorros G, Jaff MR, Dorros AM, Mathiak LM, He T. Tibioperoneal (outflow lesion) angioplasty can be used as primary treatment in 235 patients with critical limb ischemia: five-year follow-up. Circulation 2001;104:2057-62. (Pubitemid 33027046)
7. Boyer L, Therre T, Garcier JM, Perez N, Ravel A, Privat C et al. Infrapopliteal percutaneous transluminal angioplasty for limb salvage. Acta Radiol 2000;41:73-7.
8. Buckenham TM, Loh A, Dormandy JA, Taylor RS. Infrapopliteal angioplasty for limb salvage. Eur J Vasc Surg 1993:7:21-5.
9. Sixt S, Alawied AK, Rastan A, Schwarzwälder U, Noory E, Schwarz T et al. Acute and Long-term Outcome of or Aorto-iliac Endovascular Therapy According to the TASC Classification: A Single Centre Experience. JEVT 2008;15:408-16.
10. Krankenberg H, Schlüter M, Steinkamp HJ, Bürgelin K, Scheinen: D, Schulte CL et al. Nitinol stent implantation vs. percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the femoral artery stenting trial (FAST). Circulation 2007;116:285-92.
11. Sabeti S, Mlekusch W, Amighi J, Minar E, Schillinger M. Primary patency of long-segment self-expanding nitinol stents in the femoropopliteal arteries. J Endovasc Ther 2005;12:6-12. (Pubitemid 40229383)
12. Heldman AW, Cheng L, Jenkins GM, Heller PF, Kim DW, Ware M Jr et al. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 2001;103:2289-95. (Pubitemid 32433720)
13. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-80. (Pubitemid 34586912)
14. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy CC et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23. (Pubitemid 37186209)
15. Duda SH, Bosiers M, Lammer J, Scheinert D, Zeller T, Tielbeek A et al. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial. J Vasc Interv Radiol 2005;16:331-8. (Pubitemid 40354849)
16. Duda SH, Bosiers M, Lammer J, Scheinert D, Zeller T, Oliva V et al. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: Long-term results from the SIROCCO trial. J Endovasc Ther 2006;13:701-10. (Pubitemid 44907633)
17. Scheinen D, Ulrich M, Scheinert S, Sax J, Bräunlich S, Biamino G. Comparison of sirolimus-eluting vs. bare-metal stents for the treatment of infrapopliteal obstructions. Eurointervention 2006;2:169-74.
18. Siablis D, Karnabatidis D, Katsanos K, Kagadis GC, Kraniotis P, Diamantopoulos A et al. Sirolimus-eluting versus bare stents after suboptimal infrapopliteal angioplasty for critical limb ischemia: enduring 1-year angiographic and clinical benefit. J Endovasc Ther 2007;14:241-50. (Pubitemid 46776123)
19. Bosiers M, Deloose K, Verbist J, Peeters P. Percutaneous transluminal angioplasty for treatment of "below-the-knee" critical limb ischemia: early outcomes following the use of sirolimus-eluting stents. J Cardiovasc Surg (Torino) 2006;47:171-6.
20. Rosales OR, Mathewkutty S, Gnaim C. Drug eluting stents for below the knee lesions in patients with critical limb ischemia: long-term follow-up. Catheter Cardiovasc Interv 2008;72:112-5. (Pubitemid 352008995)
21. Grant AG, White CJ, Collins TJ, Jenkins JS, Reilly JP, Ramee SR. Infrapopliteal drug-eluting stents for chronic limb ischemia. Catheter Cardiovasc Interv 2008;71:108-11. (Pubitemid 351158354)
22. Feiring AJ, Krahn M, Nelson L, Wesolowski A, Eastwood D, Szabo A. Preventing leg amputations in critical limb ischemia with below-the-knee drug-eluting stents: the PaRADISE (PReventing Amputations using Drug eluting StEnts) trial. J Am Coll Cardiol 2010;55:1580-9.
23. Balzer JO, Zeller T, Rastan A, Sixt S, Kahn V, Vogl TJ et al. Percutaneous interventions below the knee in patients with critical limb ischemia using drug eluting stents. J Cardiovasc Surg 2010;51:183-91.
24. Rastan A, Schwarzwälder U, Noory E, Haj Taib F, Beschorner U, Sixt S et al. Primary use of sirolimus-eluting stents for angioplasty of infrapopliteal arteries. J Endovasc Ther 2010;17:480-7.
25. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-30.
26. Bavry AA, Kumbhani DJ, Helton TJ, Borek PP, Mood GR, Bhatt DL. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med 2006;119:1056-61. (Pubitemid 44826931)
27. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48:193-202.
28. Hwang CW, Wu D, Edelman ER. Physiological transport forces govern drug distribution for stent-based delivery. Circulation 2001;104:600-5. (Pubitemid 32738132)
29. Kamath KR, Barry JJ, Miller KM. The Taxus drug-eluting stent: a new paradigm in controlled drug delivery. Adv Drug Deliv Rev 2006;58:412-36. (Pubitemid 43949060)
30. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979;277:665-7. (Pubitemid 9114288)
31. Zargham R. Preventing restenosis after angioplasty: a multi-stage approach. Clin Sci (Lond) 2008;114:257-64. (Pubitemid 351294001)
32. Ge H, Zhou Y, Hanying M, Liu L, Nie X, Wang Z et al. Influence of drug-eluting stent on inflammation during restenosis in a porcine coronary model. Acta Cardiol 2010;65:31-5.
33. Axel DI, Kunert W, Göggelmann C, Oberhoff M, Herdeg C, Küttner A et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997;96:636-45. (Pubitemid 27329445)
34. Scheller B, Speck U, Schmitt A, Bohm M, Nickenig G. Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation. J Am Coll Cardiol 2003;42:1415-20. (Pubitemid 37267283)
35. Scheller B, Speck U, Romeike B, Schmitt A, Sovak M, Böhm M et al. Contrast media as carriers for local drug delivery. Successful inhibition of neointimal proliferation in the porcine coronary stent model. Eur Heart J 2003;24:1462-7.
36. Speck U, Scheller B, Abramjuk C, Breitwieser C, Dobberstein J, Boehm M et al. Neointima inhibition: comparison of effectiveness of non-stent-based local drug delivery and a drug-eluting stent in porcine coronary arteries. Radiology 2006;240:411-8. (Pubitemid 44098636)
37. Scheller B, Speck U, Abramjuk C, Bernhardt U, Böhm M, Nickenig G. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation 2004;110:810-4.
38. Speck U, Scheller B, Abramjuk C, Breitwieser C, Dobberstein J, Boehm M et al. Neointima inhibition: comparison of effectiveness of non-stent-based local drug delivery and a drug-eluting stent in porcine coronary arteries. Radiology 2006;240:411-8. (Pubitemid 44098636)
39. Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med 2006;355:2113-24. (Pubitemid 44749319)
40. Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U et al. Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. Clin Res Cardiol 2008;97:773-81.
41. Cremers B, Speck U, Kaufels N, Mahnkopf D, Kühler M, Böhm M et al. Drug-eluting balloon: very short-term exposure and overlapping. Thromb Haemost 2009;101:201-6.
42. Tepe G, Zeller T, Albrecht T, Heller S, Schwarzwälder U, Beregi JP et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med 2008;358:689-99. (Pubitemid 351240748)
43. Albrecht T, Speck U, Baier C, Wolf KJ, Böhm M, Scheller B. Reduction of stenosis due to intimai hyperplasia after stent supported angioplasty of peripheral arteries by local administration of paclitaxel in swine. Invest Radiol 2007;42:579-85. (Pubitemid 47051835)
44. Werk M, Langner S, Reinkensmeier B, Boettcher HF, Tepe G, Dietz U et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation 2008;118:1358-65.
45. Zeller T, Rastan A, Schwarzwälder U, Schwarz T, Frank U, Bürgelin K et al. Long-term results after directional atherectomy of femoro-popliteal lesions. JACC 2006;48:1573-8. (Pubitemid 44528188)
46. Zeller T, Sixt S, Schwarzwälder U, Müller C, Schwarz T, Frank U et al. Two-year results after directional atherectomy of infrapopliteal arteries with the Silverhawk device. JEVT 2007;14:232-40.
47. Ishii H, Kumada Y, Toriyama T, Aoyama T, Takahashi H, Tanaka M et al. Effects of oral cilostazol 100 mg BID on long-term patency after percutaneous transluminal angioplasty in patients with femoropopliteal disease undergoing hemodialysis: a retrospective chart review in Japanese patients. Clin Ther 2010;32:24-33.
48. Soga Y, Yokoi H, Kawasaki T, Nakashima H, Tsurugida M, Hikichi Y et al. Efficacy of cilostazol after endovascular therapy for femoropopliteal artery disease in patients with intermittent claudication. J Am Coll Cardiol 2009;53:48-53.